ΓΕΝΙΚΕΣ |
|
Thrombophilia (Hemostasis) (13 mutations) FV G1691A (Leiden), FV H1299R (R2), Prothrombin G20210A, Factor XIII V34L, β-Fibrinogen -455 G-A, PAI-1 4G/5G, GPIIIa L33P (HPA-1), GP1a 807 C-T, MTHFR C677T, MTHFR A1298C, ACE I/D, Apo B R3500Q, Apo E2/E3/E4 |
|
Μεμονωμένες μεταλλάξεις θρομβοφιλίας |
|
Hemochromatosis (12 HFE, 4 TFR2 and 2 FPN1) 12 mutations in the HFE gene (V53M, V59M, H63D, H63H, S65C, Q127H, P160delC, E168Q, E168X, W169X, C282Y, Q283P), 4 mutations in the TFR2 gene (E60X, M172K, Y250X, AVAQ594-597del), and 2 mutations in the FPN1 gene (N144H, V162del) |
|
CMV Quantitative |
|
NGS PANEL DNA 38 GENES |
|
ATM, BRAF, BTK , CBL, CSF3R, CXCR4, DNMT3A,FBXW7, FLT3,IDH1, IDH2, JAK1, JAK2, MPL, MYD88,NOTCH1, NPM1,NRAS,PAX5,PLCG2, RHOA,SETBP1,SF3B1,SRSF2,U2AF1, ASXL1,CALR, CEBPA,ETV6, EZH2, IKZF1, IKZF2, IKZF3, RUNX1, STAG2,TET2, TP53, ZRSR2 |
|
ΧΡΟΝΙΑ ΜΥΕΛΟΓΕΝΗΣ ΛΕΥΧΑΙΜΙΑ |
|
BCR-ABL (P210, P190, P230) screening |
|
BCR-ABL P210 Quantitative |
|
BCR-ABL P190 Quantitative |
|
BCR-ABL P230 Quantitative |
|
ABL mutations |
|
ΜΥΕΛΟΫΠΕΡΠΛΑΣΤΙΚΑ ΝΕΟΠΛΑΣΜΑΤΑ Ph- |
|
JAK2 V617F |
|
JAK2 Exon12 mutations |
|
CALR indels |
|
MPL W515 mutations |
|
EPOR mutations |
|
ΗΩΣΙΝΟΦΙΛΙΑ |
|
FIP1L1-PDGFRA |
|
ΜΑΣΤΟΚΥΤΤΑΡΩΣΗ |
|
CKIT D816V |
|
ΧΡΟΝΙΑ ΟΥΔΕΤΕΡΟΦΙΛΙΚΗ ΛΕΥΧΑΙΜΙΑ / ΑΤΥΠΗ ΧΡΟΝΙΑ ΜΥΕΛΟΓΕΝΗΣ ΛΕΥΧΑΙΜΙΑ |
|
CSF3R mutations |
|
ΟΞΕΙΑ ΜΥΕΛΟΓΕΝΗΣ ΛΕΥΧΑΙΜΙΑ |
|
FLT3 ITD mutations |
|
FT3 TKD mutations |
|
NPM1 mutations |
|
NPM1(mutation type A,B,D) Quantitative |
|
PML-RARA (bcr1, bcr2, bcr3) screening |
|
PML-RARA bcr1 Quantitative |
|
PML-RARA bcr2 Quantitative |
|
PML-RARA bcr3 Quantitative |
|
CBFB-MYH11 screening |
|
CBFB-MYH11 quantitative |
|
RUNX1-RUNX1T1 screening |
|
RUNX1-RUNX1T1 quantitative |
|
NGS PANEL DNA 38 GENES |
|
ΟΞΕΙΑ ΛΕΜΦΟΒΛΑΣΤΙΚΗ ΛΕΥΧΑΙΜΙΑ |
|
Patient Specific Clone Detection (NGS) |
|
Patient Specific Clone MRD (NGS) |
|
ALL Panel kit screening (8 translocations) E2A-PBX1, TEL-AML1, MLL-AF4, MLL-ENL, MLL-AF9, MLL-AF6, MLL-AF10, BCR-ABL1 |
|
Μεμονωμένες αναδιατάξεις E2A-PBX1, TEL-AML1, MLL-AF4, MLL-ENL, MLL-AF9, MLL-AF6, MLL-AF10, BCR-ABL1 |
|
BCR-ABL (P210, P190, P230) screening |
|
BCR-ABL P210 Quantitative |
|
BCR-ABL P190 Quantitative |
|
BCR-ABL P230 Quantitative |
|
ABL mutations |
|
ΤΡΙΧΩΤΗ ΛΕΥΧΑΙΜΙΑ |
|
BRAF V600E |
|
ΜΑΚΡΟΣΦΑΙΡΙΝΑΙΜΙΑ WALDENSTROM |
|
MYD88 L265P |
|
CXCR4 mutations |
|
ΧΡΟΝΙΑ ΛΕΜΦΟΚΥΤΤΑΡΙΚΗ ΛΕΥΧΑΙΜΙΑ |
|
IGVH υπερμεταλλάξεις |
|
TP53 mutations |
|
TP53 mutations (NGS) |
|
NGS PANEL DNA 38 GENES |
|
ΛΕΜΦΟΫΠΕΡΠΛΑΣΤΙΚΑ ΝΟΣΗΜΑΤΑ |
|
B Cell Clonality (NGS) |
|
T Cell Clonality (TCRβ) (NGS) |
|
T Cell Clonality (TCRγ) (NGS) |
|
NGS PANEL DNA 38 GENES |